Hyein Kim1, Frédéric Lefebvre2, Sabrina Hoa2,3, Marie Hudson4,5. 1. Division of Rheumatology, Department of Medicine, University of British Columbia, Vancouver, BC, Canada. 2. Division of Rheumatology, Department of Medicine, Université de Montréal, Montreal, QC, Canada. 3. Centre Hospitalier de l'Université de Montréal Research Center, Montreal, QC, Canada. 4. Lady Davis Institute, Jewish General Hospital, Montreal, QC, Canada. 5. Department of Medicine, McGill University, Montreal, QC, Canada.
Abstract
Objectives: The objective of this study was to systematically review the mortality and morbidity associated with scleroderma renal crisis and to determine temporal trends. Methods: We searched MEDLINE, Embase and the Cochrane Database of Systematic Reviews from database inception to 10 February 2020. Bibliographies of selected articles were hand-searched for additional references. Data were extracted using a standardized extraction form. Study quality was assessed using the Newcastle-Ottawa scale. Results were analysed qualitatively. Results: Twenty studies with 14,059 systemic sclerosis subjects, of which 854 had scleroderma renal crisis and 4095 had systemic sclerosis-associated end-stage renal disease, met inclusion criteria. Study quality was generally moderate. Cumulative mortality in the post-angiotensin-converting enzyme inhibitor era was approximately 20% at 6 months, 30%-36% at 1 year, 19%-40% at 3 years and almost 50% at 10 years from scleroderma renal crisis onset. Although the introduction of angiotensin-converting enzyme inhibitors in the early 1970s resulted in a 50% improvement in scleroderma renal crisis mortality, there was no further improvement thereafter. Scleroderma renal crisis mortality rates were proportionally higher than mortality rates associated with other systemic sclerosis organ involvement. The rate of permanent dialysis after scleroderma renal crisis in the post-angiotensin-converting enzyme inhibitor era ranged from 19%-40%. Three to 17% of systemic sclerosis patients underwent renal transplant. Survival was better in patients post-renal transplant (54%-91%) compared to those on dialysis (31%-56%). Graft survival improved over time and appeared similar to that of patients with other types of end-stage renal disease. Conclusion: While there has been considerable improvement in scleroderma renal crisis-related outcomes since the introduction of angiotensin-converting enzyme inhibitors, morbidity and mortality remain high for affected patients without convincing evidence of further improvement in the post-angiotensin-converting enzyme inhibitor era. Novel treatments are required to improve outcomes of scleroderma renal crisis.
Objectives: The objective of this study was to systematically review the mortality and morbidity associated with scleroderma renal crisis and to determine temporal trends. Methods: We searched MEDLINE, Embase and the Cochrane Database of Systematic Reviews from database inception to 10 February 2020. Bibliographies of selected articles were hand-searched for additional references. Data were extracted using a standardized extraction form. Study quality was assessed using the Newcastle-Ottawa scale. Results were analysed qualitatively. Results: Twenty studies with 14,059 systemic sclerosis subjects, of which 854 had scleroderma renal crisis and 4095 had systemic sclerosis-associated end-stage renal disease, met inclusion criteria. Study quality was generally moderate. Cumulative mortality in the post-angiotensin-converting enzyme inhibitor era was approximately 20% at 6 months, 30%-36% at 1 year, 19%-40% at 3 years and almost 50% at 10 years from scleroderma renal crisis onset. Although the introduction of angiotensin-converting enzyme inhibitors in the early 1970s resulted in a 50% improvement in scleroderma renal crisis mortality, there was no further improvement thereafter. Scleroderma renal crisis mortality rates were proportionally higher than mortality rates associated with other systemic sclerosis organ involvement. The rate of permanent dialysis after scleroderma renal crisis in the post-angiotensin-converting enzyme inhibitor era ranged from 19%-40%. Three to 17% of systemic sclerosis patients underwent renal transplant. Survival was better in patients post-renal transplant (54%-91%) compared to those on dialysis (31%-56%). Graft survival improved over time and appeared similar to that of patients with other types of end-stage renal disease. Conclusion: While there has been considerable improvement in scleroderma renal crisis-related outcomes since the introduction of angiotensin-converting enzyme inhibitors, morbidity and mortality remain high for affected patients without convincing evidence of further improvement in the post-angiotensin-converting enzyme inhibitor era. Novel treatments are required to improve outcomes of scleroderma renal crisis.
Authors: Manuel Rubio-Rivas; Xavier Corbella; Melany Pestaña-Fernández; Carles Tolosa-Vilella; Alfredo Guillen-Del Castillo; Dolores Colunga-Argüelles; Luis Trapiella-Martínez; Nerea Iniesta-Arandia; María Jesús Castillo-Palma; Luis Sáez-Comet; María Victoria Egurbide-Arberas; Norberto Ortego-Centeno; Mayka Freire; Jose Antonio Vargas-Hitos; Juan José Ríos-Blanco; Jose Antonio Todolí-Parra; Mónica Rodríguez-Carballeira; Adela Marín-Ballvé; Pablo Segovia-Alonso; Xavier Pla-Salas; Ana Belén Madroñero-Vuelta; Manuel Ruiz-Muñoz; Vicent Fonollosa-Pla; Carmen Pilar Simeón-Aznar; E Callejas Moraga; E Calvo; C Carbonell; M J Castillo; A J Chamorro; D Colunga; X Corbella; M V Egurbide; G Espinosa; V Fonollosa; M Freire; F J García Hernández; R González León; A Guillén Del Castillo; N Iniesta; R Lorenzo; A B Madroñero; B Marí; A Marín; N Ortego-Centeno; M Pérez Conesa; M Pestaña; X Pla; J J Ríos Blanco; M Rodríguez Carballeira; M Rubio Rivas; M Ruiz Muñoz; L Sáez Comet; P Segovia; C P Simeón; A Soto; E Tarí; J A Todolí; C Tolosa; L Trapiella; J A Vargas Hitos; G Verdejo Journal: Clin Rheumatol Date: 2017-12-07 Impact factor: 2.980
Authors: Zdenka Hruskova; Maria Pippias; Vianda S Stel; Jose M Abad-Díez; Manuel Benítez Sánchez; Fergus J Caskey; Frederic Collart; Johan De Meester; Patrik Finne; James G Heaf; Angela Magaz; Runolfur Palsson; Anna Varberg Reisæter; Alan D Salama; Mårten Segelmark; Jamie P Traynor; Ziad A Massy; Kitty J Jager; Vladimir Tesar Journal: Am J Kidney Dis Date: 2018-08-16 Impact factor: 8.860
Authors: Anthony J Tyndall; Bettina Bannert; Madelon Vonk; Paolo Airò; Franco Cozzi; Patricia E Carreira; Dominique Farge Bancel; Yannick Allanore; Ulf Müller-Ladner; Oliver Distler; Florenzo Iannone; Raffaele Pellerito; Margarita Pileckyte; Irene Miniati; Lidia Ananieva; Alexandra Balbir Gurman; Nemanja Damjanov; Adelheid Mueller; Gabriele Valentini; Gabriela Riemekasten; Mohammed Tikly; Laura Hummers; Maria J S Henriques; Paola Caramaschi; Agneta Scheja; Blaz Rozman; Evelien Ton; Gábor Kumánovics; Bernard Coleiro; Eva Feierl; Gabriella Szucs; Carlos Alberto Von Mühlen; Valeria Riccieri; Srdan Novak; Carlo Chizzolini; Anna Kotulska; Christopher Denton; Paulo C Coelho; Ina Kötter; Ismail Simsek; Paloma García de la Pena Lefebvre; Eric Hachulla; James R Seibold; Simona Rednic; Jirí Stork; Jadranka Morovic-Vergles; Ulrich A Walker Journal: Ann Rheum Dis Date: 2010-06-15 Impact factor: 19.103
Authors: Donald P Tashkin; Michael D Roth; Philip J Clements; Daniel E Furst; Dinesh Khanna; Eric C Kleerup; Jonathan Goldin; Edgar Arriola; Elizabeth R Volkmann; Suzanne Kafaja; Richard Silver; Virginia Steen; Charlie Strange; Robert Wise; Fredrick Wigley; Maureen Mayes; David J Riley; Sabiha Hussain; Shervin Assassi; Vivien M Hsu; Bela Patel; Kristine Phillips; Fernando Martinez; Jeffrey Golden; M Kari Connolly; John Varga; Jane Dematte; Monique E Hinchcliff; Aryeh Fischer; Jeffrey Swigris; Richard Meehan; Arthur Theodore; Robert Simms; Suncica Volkov; Dean E Schraufnagel; Mary Beth Scholand; Tracy Frech; Jerry A Molitor; Kristin Highland; Charles A Read; Marvin J Fritzler; Grace Hyun J Kim; Chi-Hong Tseng; Robert M Elashoff Journal: Lancet Respir Med Date: 2016-07-25 Impact factor: 30.700